Valeant under Pressure From US Legislators

Shares of US-listed Canadian drugmaker Valeant came under additional severe pressure early this week when Democratic party members on the House of Representative committee on oversight and government reform called on the committee’s Republican leadership to issue a subpoena against the company.

The legislators want to force Valeant to hand over documents relating to what they called “massive price hikes” for generic cardiovascular drugs Isuprel (up 212%) and Nitropress (up 525%). They also called for Valeant chairman Mike Pearson as well as Martin Shkreli of Turing Pharmaceuticals to testify in front of the committee.

Shkreli came to public attention recently with his announcement of a 50-fold price increase for Daraprim (pyrimethamine), an off-patent drug for treating the deadly parasitic infection toxoplasmosis. Both companies increased prices shortly after acquiring rights to the medications.

“Valeant is using precisely the same business model as Martin Shkreli,” the committee members said, adding that both appear to be acquiring potentially life-saving drugs to maximize their own corporate profits. The legislators said they believe “it is critical to hold drug companies to account when they engage in a business strategy of buying old neglected drugs and turning them into high-priced ‘specialty’ drugs.”

A rebuke for Turing from US presidential candidate Hillary Clinton led all US-listed pharmaceutical and biotech stocks to plummet last week, with Valeant taking the worst hit. US investors are reported to be selling off pharmaceutical company positions amid concerns that the industry will face greater pricing pressures ahead of the November 2016 US presidential election.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.